Patents by Inventor Scott D. Kuduk
Scott D. Kuduk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220153754Abstract: Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of CAM1. Such compounds are represented by Formula (I) as follows: wherein, R1, R1A, R2, R3, R4, HET, n, X, Y, Z1 and Z2 are defined herein.Type: ApplicationFiled: May 27, 2020Publication date: May 19, 2022Inventor: Scott D. KUDUK
-
Publication number: 20220064147Abstract: The present disclosure is directed to pyrimidone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV nave cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).Type: ApplicationFiled: December 13, 2019Publication date: March 3, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Antonella Converso, Abdellatif El Marrouni, Ashley Forster, Jessica L. Frie, David N. Hunter, Scott D. Kuduk, Helen J. Mitchell, Philippe Nantermet, Deyou Sha, William Daniel Shipe, Cheng Wang, Deping Wang
-
Patent number: 10526336Abstract: The present invention is directed to fused heteroaryl derivative compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: December 18, 2015Date of Patent: January 7, 2020Assignee: Merck, Sharp & Dohme Corp.Inventors: Scott D. Kuduk, Nigel Liverton, Douglas C. Beshore, Na Meng, Yunfu Luo
-
Patent number: 10435398Abstract: The present invention is directed to oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the oxazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: October 27, 2015Date of Patent: October 8, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Scott D. Kuduk, Nigel Liverton, Yunfu Luo
-
Patent number: 10308645Abstract: The present invention is directed to piperidine oxadiazole and thiadiazole orexin compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: September 27, 2015Date of Patent: June 4, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Nigel Liverton, Scott D. Kuduk, Yunfu Luo, Na Meng, Tingting Yu
-
Patent number: 10239838Abstract: The present invention is directed to heteroaryl compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: December 14, 2015Date of Patent: March 26, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Scott D. Kuduk, Nigel Liverton, Yunfu Luo
-
Patent number: 10227336Abstract: The present invention is directed to pyrazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the pyrazole compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: October 27, 2015Date of Patent: March 12, 2019Assignee: Merck Sharp & Dohme CorpInventors: Nigel Liverton, Scott D. Kuduk, Yunfu Luo
-
Patent number: 10214535Abstract: The present invention is directed to hydroxymethyl piperidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: November 30, 2015Date of Patent: February 26, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Scott D. Kuduk, Nigel Liverton, Yunfu Luo
-
Publication number: 20180370973Abstract: The present invention is directed to fused heteroaryl derivative compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: ApplicationFiled: December 18, 2015Publication date: December 27, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Scott D. Kuduk, Nigel Liverton, Douglas C. Beshore, Na Meng, Yunfu Luo
-
Patent number: 10155750Abstract: The present invention is directed to amidoethyl azole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: December 18, 2015Date of Patent: December 18, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Scott D. Kuduk, Nigel Liverton, Yunfu Luo
-
Patent number: 10150751Abstract: The present invention is directed to pyrrolidine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: December 14, 2015Date of Patent: December 11, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Scott D. Kuduk, Nigel Liverton, Yunfu Luo, Jason W. Skudlarek
-
Patent number: 10017504Abstract: The present invention is directed to piperidine isoxazole and isothiazole orexin compounds which are antagonists of orexin receptors. Such compounds are of the general structural formula I: wherein the variables are defined herein. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: October 27, 2015Date of Patent: July 10, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Nigel Liverton, Scott D. Kuduk, Douglas Beshore, Yunfu Luo, Na Meng, Tingting Yu
-
Patent number: 10010539Abstract: The present invention is directed to pyrazole, triazole and tetrazole compounds which are antagonists of orexin receptors. Such compounds are of the general structural formula I: The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: October 27, 2015Date of Patent: July 3, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Nigel Liverton, Scott D. Kuduk, Douglas Beshore, Yunfu Luo, Na Meng
-
Patent number: 10011595Abstract: The present invention is directed to ethyldiamne compounds which are antagonists of orexin receptors. Such compounds are of the general structural formula I: The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: December 14, 2015Date of Patent: July 3, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Ronald M. Kim, Scott D. Kuduk, Nigel Liverton, Gang Zhou
-
Patent number: 10000499Abstract: The present invention is directed to methyl diazepane compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: November 20, 2015Date of Patent: June 19, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Scott D. Kuduk, Thomas S. Reger, Jason W. Skudlarek
-
Patent number: 9994570Abstract: The present invention is directed to bridged diazepane compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: November 20, 2015Date of Patent: June 12, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Scott D. Kuduk, Thomas S. Reger, Anthony J. Roecker
-
Patent number: 9987255Abstract: The present invention is directed to 5,5-bicyclic oxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: December 14, 2015Date of Patent: June 5, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Scott D. Kuduk, Nigel Liverton, Thomas S. Reger, Jason W. Skudlarek
-
Patent number: 9975876Abstract: The present invention is directed to 2-pyridyloxy-3-ester-4-ether compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the 2-pyridyloxy-4-ether compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to pharmaceutical compositions comprising these compounds. The present invention is also directed to uses of these pharmaceutical compositions in the prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: December 4, 2014Date of Patent: May 22, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Scott D. Kuduk, Jason W. Skudlarek
-
Patent number: 9938276Abstract: The present invention is directed to 6,5-bicyclic octahydropyrrolopyridine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: December 14, 2015Date of Patent: April 10, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Ronald M. Kim, Scott D. Kuduk, Nigel Liverton, Gang Zhou
-
Patent number: 9920038Abstract: The present invention is directed to methyloxazole compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.Type: GrantFiled: November 30, 2015Date of Patent: March 20, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Scott D. Kuduk, Nigel Liverton, Yunfu Luo